MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 06, 2024 06:05 ET
|
MannKind
MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE
Interstitial Cystitis Drugs Global Market Report 2024, By Drugs (Pentosan Polysulfate Sodium; Dimethyl Sulfoxide), By Type (Oral Therapy; Intravesical Therapy) and By Distribution Channel
May 06, 2024 04:06 ET
|
Research and Markets
Dublin, May 06, 2024 (GLOBE NEWSWIRE) -- The "Interstitial Cystitis Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The interstitial cystitis drugs...
Global Migraine Drugs Market Report 2024, By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants), By Route of Administration (Oral, Injectable) and By End-User
May 06, 2024 04:05 ET
|
Research and Markets
Dublin, May 06, 2024 (GLOBE NEWSWIRE) -- The "Migraine Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The migraine drugs market size has grown strongly...
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
May 03, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1...
Global Fill Finish Manufacturing Market Report 2024-2029, with Leading Players Syntegon, Gerresheimer, AptarGroup, Datwyler, Stevanato, OPTIMA, Bausch+Strobel, Groninger, SGD PHARMA, SCHOTT and Nipro
May 01, 2024 04:02 ET
|
Research and Markets
Dublin, May 01, 2024 (GLOBE NEWSWIRE) -- The "Global Fill Finish Manufacturing Market by Product (Consumables (Pre-fillable Syringes (Plunger Stopper)), Vial (Glass, Plastic), Cartridge),...
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
April 30, 2024 14:40 ET
|
Spherix Global Insights
EXTON, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by the persistent...
RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine
April 30, 2024 10:00 ET
|
RS BioTherapeutics
RS BioTherapeutics announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine.
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
April 29, 2024 08:00 ET
|
Phathom Pharmaceuticals
Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical...
Tocopherol Market Size is Expected to Reach USD 2,288.73 million by 2030, Growing at a CAGR of 8.75%: Straits Research
April 24, 2024 10:51 ET
|
Straits Research Private Limited - Reed Intelligence
New York, United States, April 24, 2024 (GLOBE NEWSWIRE) -- Tocopherol, a type of fat-soluble vitamin E active component, is well known as an antioxidant. It's a protective element that only...
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
April 24, 2024 07:00 ET
|
atai Life Sciences
The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.Initial results from the recently...